AbbVie (NYSE: ABBV) reported that upadacitinib (RINVOQ) achieved co-primary endpoints in two Phase 3 studies evaluating the drug in adults ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE